<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63635">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740037</url>
  </required_header>
  <id_info>
    <org_study_id>METC 11-2-099</org_study_id>
    <nct_id>NCT01740037</nct_id>
  </id_info>
  <brief_title>IntegRAted CarE for Atrial Fibrillation - RACE-4</brief_title>
  <acronym>RACE-4</acronym>
  <official_title>IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, a Multicenter Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Achmea Gezondheidszorg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DSW</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CZ fonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The treatment of patients with atrial fibrillation is often inadequate due to
      poor guideline adherence. An integrated chronic care program (ICCP) at a specialized
      AF-clinic was found to be superior to usual care provided by a cardiologist in terms of
      cardiovascular hospitalizations and cardiovascular mortality.

      Hypothesis: treatment at a specialized AF clinic is superior to usual care in terms of
      cardiovascular mortality and cardiovascular hospitalizations, cost-effectiveness, quality of
      life and guideline adherence.

      Objectives: primary objective is to show that an ICCP reduces cardiovascular
      hospitalizations and mortality. The secondary objectives include cost-effectiveness,
      guideline adherence, quality of life, patient knowledge and patient compliance in
      medication.

      Study design: randomized controlled trial with two study arms: usual care provided by
      cardiologists (control) versus ICCP at a specialized AF-clinic (intervention) in 9 hospitals
      in the Netherlands. In total 1716 patients with newly diagnosed AF will be included. Total
      duration of the study is 4,5 years and total mean follow-up will be 2,4 years. Data
      collected at inclusion, after 3, 6, 12 months and every year thereafter.

      Study population: Patients older than 18 year with newly diagnosed AF.

      Intervention: treatment through an ICCP at specialized AF clinics, consisting of a nurse
      specialist, cardiologist-supervisor and a guidelines-based information-communication
      technology (ICT) decision support program and a web-based patient centered medication
      management tool and tailored telemonitoring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary endpoint is a composite of unplanned admission to the hospital for any cardiovascular reason and cardiovascular death.</measure>
    <time_frame>Participants will be followed at yearly intervals, an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The endpoint events associated with hospitalisation or death are
Left or right ventricular heart failure which is independent of left ventricular ejection fraction (LVEF) and requiring intravenous diuretics;
Ischemic thromboembolic complications including stroke, peripheral, pulmonary or systemic emboli (confirmed by a neurologist on the basis of computerised tomography or MRI);
Acute coronary syndrome (acute myocardial infarction or instable angina pectoris, with two of the following characteristics: chest pain and/ or ischemic electrocardiographic changes, and/ or cardiac enzyme rise);
Bleeding (a bleeding with the hemoglobin value decreased by &gt; 20 g/ L (&gt;2g/ dL) or requiring blood transfusion
Arrhythmic or potential arrhythmic events (atrial fibrillation, -flutter, other supraventricular rhythm or sustained ventricular tachycardia confirmed by ECG, syncope or cardiac arrest)
Life-threatening adverse effects of rate or rhythm controlling drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs and cost benefit of the intervention by means of a cost effectiveness analysis</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The extent to which the comprehensive cardiovascular treatment is in accordance to the 2010 European Society of Cardiology (ESC) AF guidelines, the 2008 ESC Heart Failure guidelines and the 2007 ESC Cardiovascular Disease Prevention guidelines</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient anxiety and/ or depression</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' knowledge of AF</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' compliance in medication</measure>
    <time_frame>Participants will be followed an expected average of 2.4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1716</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Specialized AF-clinic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Management of AF patients in specialized AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by nurse specialists, supported by  an ICT decision support tool based on professional guidelines (CardioConsult AF®) and supervised by a cardiologist. In addition, a web-based patient centered medication management tool (Medication Manager(TM)and tailored telemonitoring at an outpatient AF clinic. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care provided by cardiologists at the regular outpatient clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specialized AF Clinic</intervention_name>
    <arm_group_label>Specialized AF-clinic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly diagnosed AF detected on electrocardiogram (ECG), holder
             recordings or event recorder with a duration &gt; 30 seconds, in the 3 months before
             inclusion or

          2. Patients with a history of diagnosed AF, with no regular control at a cardiologist
             for AF in the last 2 years and referred by a (non-)cardiologic medical specialist for
             new diagnostics or therapeutic issue;

          3. Age ≥18 years.

        Exclusion Criteria:

          1. No electrocardiographic objectified AF;

          2. Unstable heart failure defined as NYHA IV or heart failure necessitating hospital
             admission &lt; 3 months before inclusion;

          3. Acute coronary syndrome (acute myocardial infarction or instable angina pectoris,
             with two of the following characteristics: chest pain and/ or ischemic
             electrocardiographic changes, and/ or cardiac enzyme rise) &lt; 3 months before
             inclusion;

          4. Untreated hyperthyroidism or &lt; 3 months euthyroidism before inclusion;

          5. Current or foreseen pacemaker, internal cardioverter defibrillator, and/ or cardiac
             resynchronization therapy;

          6. Cardiac surgery ≤ 3 months before inclusion;

          7. Planned cardiac surgery;

          8. Regular control and treatment, also for AF, at another specialized outpatient cardiac
             clinic;

          9. Patient is not able to fill in the questionnaires;

         10. Participation in other clinical study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.J.G.M. Crijns, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUMC+</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I.C. Van Gelder, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.G. Tieleman, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martini Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H.J.G.M. Crijns, prof. dr.</last_name>
    <phone>+31433875093</phone>
    <email>hjgm.crijns@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>E.P.J. Wijtvliet, MSc</last_name>
    <phone>0031(0)611363733</phone>
    <email>petra.wijtvliet@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.G. Tieleman, MD, PhD</last_name>
      <phone>+31505446245</phone>
    </contact>
    <investigator>
      <last_name>R.G. Tieleman, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I. C. Van Gelder, MD, PhD</last_name>
      <phone>+31503611327</phone>
    </contact>
    <investigator>
      <last_name>I. C. Van Gelder, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B Van Vlies, dr.</last_name>
      <phone>+31235453545</phone>
    </contact>
    <investigator>
      <last_name>B. Van Vlies, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.R. Folkeringa, drs.</last_name>
      <phone>+31582861214</phone>
    </contact>
    <investigator>
      <last_name>J.R. Folkeringa, drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. J. Crijns, MD, PhD</last_name>
      <phone>+31433875093</phone>
    </contact>
    <investigator>
      <last_name>H. J. Crijns, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.H.R. Bouwels, drs.</last_name>
      <phone>+31243658782</phone>
    </contact>
    <investigator>
      <last_name>L.H.R. Bouwels, drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.N.A. Bronzwaer, dr.</last_name>
      <phone>+31756502911</phone>
    </contact>
    <investigator>
      <last_name>P.N.A. Bronzwaer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Elvan, dr.</last_name>
      <phone>0031(0)38 - 4244273</phone>
      <email>a.elvan@isala.nl</email>
    </contact>
    <investigator>
      <last_name>A. Elvan, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic care program</keyword>
  <keyword>Nurse specialist</keyword>
  <keyword>Atrial Fibrillation guideline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
